Randomized trial finds that Compound Kushen Injection reduces tumor growth and immune evasion in HCC, suggesting enhanced therapeutic potential.
Key Points
This research aims to understand how Compound Kushen Injection (CKI) influences glycolysis and immune evasion in hepatocellular carcinoma (HCC) cells via O-GlcNAcylation.
HCC cell lines and subcutaneous transplantation mice were treated with CKI.
Glycolysis and immune evasion were analyzed post-treatment.
O-GlcNAcylation was examined using immunoprecipitation and western blotting.
CKI inhibited HCC cell viability and glycolysis and reduced immune evasion.
CKI reduced O-GlcNAc levels and inhibited OGT transcription activity.
Overexpression of OGT counteracted CKI's effect on immune evasion.